Life Sciences

  • September 21, 2026

    Ex-PetIQ CEO's Brother Admits To Illicit Trades Over Deal Info

    An Idaho man pled guilty Monday in federal court to trading on confidential information he received from his brother, the former CEO of PetIQ, about the company's acquisition by Bansk Group in August 2024.

  • September 21, 2026

    Telix Pharma Bets Up To $2.3B For ITM In Radiopharma Push

    Telix Pharmaceuticals Ltd. on Monday unveiled plans to acquire ITM Isotope Technologies Munich SE in a deal worth up to $2.3 billion that was built by three law firms.

  • September 21, 2026

    Ex-NFL Player Gets New Trial In $328M Medicare Fraud Case

    A Texas federal judge has granted a new trial for a former NFL player convicted in a $328 million Medicare billing scheme, finding that the government presented unreliable testimony and did not identify the alleged lies the defendant used to influence physicians.

  • September 21, 2026

    Medical Orgs Target Rule On Medicaid Work 'Frailty' Exclusion

    Federal regulation implementing a statutory "medical frailty" exclusion from Medicaid work requirements violates the Administrative Procedure Act, burdens healthcare providers and threatens to cause millions of people to lose their coverage, medical groups told a Maryland federal court in a complaint.

  • September 21, 2026

    Regeneron Investors Can't Use FCA Action To Support Suit

    Regeneron Pharmaceuticals Inc. and its executives have beaten a proposed class action accusing them of misleading investors about the company's revenue prospects for its vision loss drug and inflating reimbursements, with a judge ruling that the suit does not use the U.S. Department of Justice's False Claims Act suit against the company to plead share losses.

  • September 21, 2026

    Smart-Ring Maker Oura Launches $2.1B IPO Plan

    Fitness-tracking ring maker Oura on Monday unveiled a target price range for its public debut, telling the U.S. Securities and Exchange Commission that it plans to raise roughly $2.1 billion.

  • September 21, 2026

    Varian, Gov't Appeal Foreign Dividend Decision To 9th Circ.

    Varian Medical Systems Inc. is appealing a U.S. Tax Court decision that it owes more than $7.2 million to the Internal Revenue Service as a result of the court limiting its deemed dividends deduction, while the government is also appealing, according to filings in the Ninth Circuit.

  • September 21, 2026

    Sidley Lands Life Sciences Pair From King & Spalding

    Sidley Austin LLP announced Monday that it has brought on two attorneys from King & Spalding LLP to bolster its capacity to handle life sciences-related litigation and regulatory matters involving the U.S. Food and Drug Administration.

  • September 21, 2026

    Judge OKs Up To $3.2M In BioXcel Employee Ch. 11 Bonuses

    A Delaware bankruptcy judge approved employee retention and executive incentive payments that could total up to $3.2 million as AI-bolstered pharmaceutical group BioXcel works to sell its assets in Chapter 11.

  • September 18, 2026

    Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End

    Eli Lilly & Co. turned Nektar Therapeutics' autoimmune-disease drug Rezpeg into "damaged goods" by breaching the companies' co-development deal and delaying the medication's development in favor of a competing drug the pharma giant subsequently acquired, Nektar's counsel told a California federal jury during closing arguments Friday in the $1 billion case.

  • September 18, 2026

    Colo. Judge Mulls Sanction For Hospital In Gender Care Suit

    Transgender adolescent patients of Children's Hospital Colorado told a state judge the court must sanction the hospital for refusing to resume providing gender-affirming medical care for transgender youth patients, saying Friday that "nothing has changed" since the patients filed their January lawsuit.

  • September 18, 2026

    Texas Pregnancy Center Shutters To End Birth Tourism Suit

    A Texas-based pregnancy center on Friday agreed to shut down to resolve allegations by state Attorney General Ken Paxton that it helped Chinese nationals give birth in the U.S. while on tourist visas so their children could obtain birthright citizenship.

  • September 18, 2026

    Abbott's Spine Implants Cause Nerve Damage, Suit Claims

    A Pennsylvania woman is suing Abbott Laboratories and one of its subsidiaries in federal court, alleging she suffered permanent nerve damage as a result of a faulty spine implant and Abbott's representatives discouraging her from getting it removed.

  • September 18, 2026

    Conn. Town Beats Firefighter's Appeal In Pot-Use Firing Suit

    A Connecticut appellate panel declined Friday to reverse a firefighter's loss in a lawsuit he brought against the town of Waterbury after he was fired for using medical marijuana, holding that his challenge to a state court's posttrial dismissal was inadequately briefed.

  • September 18, 2026

    6th Circ. Undoes Ky. State Court Remand Of PBM Fight

    The Sixth Circuit on Friday ruled that Kentucky's lawsuit accusing pharmacy benefit managers of conspiring with drug manufacturers to increase the prescription opioid supply belongs in federal court, given the appellate court's precedential ruling from January reversing remand of another state's dispute against PBMs.

  • September 18, 2026

    Gibson Dunn Recruits 3-Partner Trial Team From Paul Weiss

    Three Paul Weiss Rifkind Wharton & Garrison LLP trial lawyers who have secured defense verdicts in some of the most high-profile product liability trials of the past decade have moved to Gibson Dunn & Crutcher LLP's mass torts and product liability practice group, the latter firm announced Friday.

  • September 18, 2026

    Cooley-Led Electra Therapeutics Prices Upsized $350M IPO

    Cooley LLP-advised Electra Therapeutics, a venture-backed biotech firm developing antibodies for immune diseases and cancer, began trading Friday after raising $350 million in an upsized IPO.

  • September 17, 2026

    Opioid MDL Judge Fears 'Chaos' If PBMs Derail 100s Of Suits

    The federal judge steering multidistrict opioid litigation is lacing into major pharmacy benefit managers for asking the Sixth Circuit to abruptly reverse a key ruling, denouncing their "spurious insinuations" about his motives and warning of disarray if they successfully break up the MDL's consolidated suits.

  • September 17, 2026

    IBM, J&J Get Incurable Data Breach Suit Tossed For Good

    A New York federal judge dismissed a proposed class action alleging IBM and Johnson & Johnson's healthcare arm failed to safeguard sensitive health information of thousands of patients before a 2023 data breach, saying he provided plaintiffs a chance to fix their complaint, and they didn't cure its "deficiencies."

  • September 17, 2026

    Justices Told Fed. Circ. Erred In Veterinary Software Feud

    A healthcare consulting services company wants the U.S. Supreme Court to review the Federal Circuit's refusal to revive its copyright and contract claims in a fight over rights to healthcare software for a U.S. Army veterinary records system.

  • September 17, 2026

    Ore. Judge Denies HHS' Attempt To Amend Gender Care Order

    An Oregon federal judge on Thursday rejected the Trump administration's bid to narrow an earlier order that voided a policy declaration central to the government's crackdown on gender-affirming care for minors.

  • September 17, 2026

    Judge OKs Omnicare Plan That Will Settle $1B In Fraud Claims

    A Texas bankruptcy judge on Thursday approved CVS unit Omnicare LLC's Chapter 11 plan, which will spin off the unit from the pharmacy megachain and settle $1 billion in federal fraud claims, after the debtor resolved all objections.

  • September 17, 2026

    Industry Groups, IP Attys Back High Court PTAB Denials Case

    The bar association for the Patent Trial and Appeal Board, a group of intellectual property law attorneys and others have urged the U.S. Supreme Court to scrutinize the discretionary denial policies of current U.S. Patent and Trademark Office leadership.

  • September 17, 2026

    Fla. Couple Says IVF Clinic Used Stranger's Sperm

    A Florida couple sued a fertility clinic Thursday alleging that it created embryos for the couple with an unknown man's sperm, which they learned after a DNA test showed their daughter has no biological connection to her father.

  • September 17, 2026

    Full Fed. Circ. Won't Rethink Pfizer's Paxlovid IP Win

    The full Federal Circuit on Thursday won't disturb a panel's refusal to revive a patent that Enanta Pharmaceuticals had accused Pfizer of infringing through its blockbuster Paxlovid COVID-19 treatment.

Expert Analysis

  • 5 Lessons For VC Investors From Del. IPO Ruling

    Author Photo

    The Delaware Court of Chancery's recent dismissal of Rostov v. Alcon Research, a derivative action over a proposed initial public offering, provides multiple practice pointers for venture capital investors, including the importance of precisely worded corporate documents and pleading a coherent theory of corporate harm, says Ben Dubin at VC Expert Services.

  • Fed. Circ. Rulings Emphasize Adjudicative Access And Review

    Author Photo

    Decisions from the Federal Circuit's 2026 docket indicate that the court is increasingly paying attention to whether tribunals possess authority to act, meaning practitioners will need to properly address procedural hurdles before they can argue the merits of a case, say attorneys at Reichman Jorgensen.

  • Series

    Being In A Band Made Me A Better Lawyer

    Author Photo

    Playing shows in storied New York City venues and rehearsing with my bandmates in poorly ventilated rooms helped develop the professional qualities I rely on as a litigator, including an ability to collaborate with strong-minded equals and the determination to treat each client with singular focus, says Eliad Shapiro at Herrick Feinstein.

  • 10th Circ. Ruling Undermines False Ad 'Two Clicks' Rule

    Author Photo

    The Tenth Circuit’s recent ruling in KetoNatural Pet Foods v. Hill's Pet Nutrition substantially challenges a long-standing assumption that a company can avoid responsibility for promotional claims simply because the consumer encountered them by clicking a hyperlink to a third-party website, say attorneys at Venable.

  • How Drug Trial Prediction Markets Pose Insider Trading Risks

    Author Photo

    Multiple prediction market platforms have recently announced plans to offer event contracts related to clinical trial outcomes and regulatory decisions, creating new insider trading risks by expanding the group of people possessing related material nonpublic information far beyond traditional corporate insiders, say attorneys at King & Spalding.

  • Mich. Ruling Gives Consumer Protection Law Its Teeth Back

    Author Photo

    The Michigan Supreme Court's recent decision in Attorney General v. Eli Lilly, overruling key holdings in two earlier cases, means that Michigan businesses can no longer defeat allegations of deceptive conduct under the state's consumer protection law simply by pointing to any governmental regulation of the business, say attorneys at DiCello Levitt.

  • Series

    Law School's Missed Lessons: Surviving A Long Trial

    Author Photo

    Most of law school trial advocacy is geared toward the sprint of trying a short case, but beyond managing a cross-examination or closing argument, effectively handling the marathon of a lengthy trial requires the ability to maintain composure, organization and credibility with the jury, says Mihir Elchuri at Hirschler.

  • AI Chatbot's Medical Claims Highlight Enforcement Risks

    Author Photo

    The Pennsylvania State Board of Medicine's recent lawsuit against Character Technologies, arguing that an artificial intelligence chatbot engaged in the unlicensed practice of medicine, may provide other state licensing boards with a road map for going after AI platforms, and counsel should advise clients to calibrate compliance accordingly, say attorneys at Cooley.

  • 7th Circ. Ruling May Reduce Litigation Risk For Text Marketers

    Author Photo

    The recent Seventh Circuit holding in Steidinger v. Blackstone Medical Services that unwanted marketing text messages are not telephone calls under the Telephone Consumer Protection Act may strengthen companies' responses to presuit demand letters and early-stage litigation claims premised on do-not-call text theories, say attorneys at Holland & Knight.

  • How Calif. Ruling Defines Drug Cos.' R&D Responsibilities

    Author Photo

    The California Supreme Court's recent ruling in the Gilead Tenofovir Cases, which held that drugmakers have no duty to bring allegedly safer alternatives to market more quickly, is a win for pharmaceutical companies — but not a grant of blanket immunity for all early-stage drug development decisions, say attorneys at King & Spalding.

  • Midyear Trends, Takeaways As Securities Class Actions Surge

    Author Photo

    High numbers of securities class actions through June suggest filings will stay elevated, with factors like changing enforcement attitudes, media scrutiny and the proliferation of potential defendants serving as both cause and effect in increased litigation involving AI-related disclosures, health and tech companies, and foreign issuers, say attorneys at Alston & Bird.

  • Series

    Going To Hardcore Shows Makes Me A Better Lawyer

    Author Photo

    While government contracts law and the hardcore scene may seem entirely unrelated, in my experience, both are about community, focus, being prepared for the unexpected and managing chaos, says Isaac Natter at Fluet.

  • How Home Infusion Providers Can Adapt To Enrollment Pause

    Author Photo

    Recent Centers for Medicare & Medicaid Services moratoria on new enrollments of home health agencies, medical equipment companies and hospices make home infusion providers' compliance obligations more complex and ambiguous, requiring new careful consideration of specific enrollment requirements and limitations, say attorneys at Quarles & Brady.

  • USPTO Practitioner Roster Reflects A More Veteran Workforce

    Author Photo

    An analysis of the U.S. Patent and Trademark Office's Office of Enrollment and Discipline practitioner roster reveals a widening demographic imbalance between new practitioners and those with more experience, but despite this trend, an expected falloff in practitioner numbers has yet to arrive, says Ian Schick at Paximal.

  • How 'Markedly Different' Test Shapes Patent Eligibility Debate

    Author Photo

    Following last month's U.S. Senate hearing on the proposed Patent Eligibility Restoration Act, it is important to examine how courts and the U.S. Patent and Trademark Office have applied the 46-year-old "markedly different characteristics" framework to determine eligibility of composition-of-matter claims, say attorneys at WilmerHale.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.